- Home
- CPIX
as 12-18-2024 3:33pm EST
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE, |
| Market Cap: | 17.2M | IPO Year: | 2009 |
| Target Price: | N/A | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $3.05 | Next Earning Date: | 11-07-2024 |
| Revenue: | $36,785,442 | Revenue Growth: | -6.45% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cumberland Pharmaceuticals Inc. (CPIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Caroline | CPIX | Director | Nov 1 '24 | Buy | $1.16 | 647 | $755.45 | 29,584 | |
| Krogulski Kenneth | CPIX | Director | Nov 1 '24 | Buy | $1.17 | 8,029 | $9,347.55 | 270,679 | |
| Jones James | CPIX | Director | Nov 1 '24 | Buy | $1.17 | 1,506 | $1,754.97 | 39,227 | |
| KAZIMI A J | CPIX | Chairman and CEO | Nov 1 '24 | Buy | $1.17 | 1,506 | $1,754.97 | 5,700,906 | |
| Young Caroline | CPIX | Director | Oct 1 '24 | Buy | $1.28 | 713 | $913.57 | 29,584 | |
| Krogulski Kenneth | CPIX | Director | Oct 1 '24 | Buy | $1.28 | 7,107 | $9,106.23 | 270,679 | |
| KAZIMI A J | CPIX | Chairman and CEO | Oct 1 '24 | Buy | $1.28 | 1,426 | $1,827.14 | 5,700,906 |
Latest Cumberland Pharmaceuticals Inc. News
CPIX Breaking Stock News: Dive into CPIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
3 Promising Penny Stocks With Market Caps Under $2B In US
GuruFocus.com
8 days ago
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change
Benzinga
8 days ago
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
MT Newswires
8 days ago
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT Newswires
8 days ago
Top Premarket Gainers
MT Newswires
9 days ago
Update: Cumberland Pharmaceuticals Gets FDA's Supplemental NDA Approval for Acetadote; Shares Jump Premarket
MT Newswires
9 days ago
Cumberland Pharmaceuticals Gets FDA's Supplemental NDA Approval for Acetadote; Shares Soar After Hours
PR Newswire
9 days ago
FDA APPROVES ACETADOTE® sNDA
Compare CPIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPIX Cumberland Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.